Abstract: Radionuclide brachytherapy sources and systems for applying beta radiation to a target area, for example for maintaining functioning drainage blebs or functioning drainage holes in the eye, e.g., to reduce intraocular pressure (IOP) of an eye being treated for glaucoma. The systems herein provide a substantially uniform dose across a particular area, thereby providing appropriate radiation therapies.

Abstract: Disclosed example gamma radiography sources include an encapsulated quantity of at least 10 Ci of Hafnium-175 (Hf-175). Disclosed example gamma radiation exposure devices include: a gamma radiation source comprising a quantity of Hf-175; and a shielding device configured to attenuate gamma radiation emitted by the gamma radiation source while the gamma radiation source is in a stored position, and configured to allow the gamma radiation source to be moved to an exposed position for gamma radiation exposure.

Abstract: The disclosure pertains to improvements in a gamma radiation source, typically containing low-density alloys or compounds or composites of iridium in mechanically deformable and compressible configurations, within a sealed encapsulation, and methods of manufacture thereof.

Abstract: The disclosure pertains to improvements in a gamma radiation source, typically containing low-density alloys or compounds or composites of iridium in mechanically deformable and compressible configurations, within a sealed encapsulation, and methods of manufacture thereof.

Abstract: The present disclosure relates to an insoluble cesium mixed multimetal oxide, ceramic, glass-ceramic or glass which is intended to be a replacement for cesium chloride or similar materials used as radiation sources. Additionally, this insoluble compound could replace other insoluble lower specific activity cesium compounds used in industrial, underwater, and underground/downhole application because it would allow the use of older lower specific activity cesium stock solutions. The disclosure further provides a method for the cesium to be recovered from cesium chloride sources.

Abstract: A radioactive or activatable seed for use in brachytherapy, and a method for producing the seed, the seed comprising a closed and self-supported casing consisting of (a) a radioactive or activatable metallic material selected from the group consisting of a metal, an alloy and a metal composite or mixtures thereof, optionally in combination with (b) a non-radioactive, non-activatable metallic material; wherein (a) comprises a radioactive nuclide selected from the group consisting of Pd-103, Tm-170, Sr-90, Y-90, Yb-169, P-32, Ge-71, Se-75, Cl-36, Ta-182, Tl-204, Re-188, W-188, Ce-144, Pr-144, Sn-123, Ru-106, Rh-106 and mixtures thereof, and/or an activatable precursor nuclide thereof selected from the group consisting of Pd-102, Rh-103, Tm-169, Y-89, Yb-168, P-31, Ge-70, Se-74, Cl-35, Ta-181, Tl-203, W-186, Sn-122 and mixtures thereof, excluding metallic Pd with natural abundance of Pd-102.

Abstract: A radioactive or activatable seed for use in brachytherapy, and a method for producing the seed, the seed comprising a closed and self-supported casing consisting of (a) a radioactive or activatable metallic material selected from the group consisting of a metal, an alloy and a metal composite or mixtures thereof, optionally in combination with (b) a non-radioactive, non-activatable metallic material; wherein (a) comprises a radioactive nuclide selected from the group consisting of Pd-103, Tm-170, Sr-90, Y-90, Yb-169, P-32, Ge-71, Se-75, Cl-36, Ta-182, Tl-204, Re-188, W-188, Ce-144, Pr-144, Sn-123, Ru-106, Rh-106 and mixtures thereof, and/or an activatable precursor nuclide thereof selected from the group consisting of Pd-102, Rh-103, Tm-169, Y-89, Yb-168, P-31, Ge-70, Se-74, Cl-35, Ta-181, Tl-203, W-186, Sn-122 and mixtures thereof, excluding metallic Pd with natural abundance of Pd-102.